The United Kingdom and the United States have signed a major trade agreement that will ensure no import taxes on British pharmaceutical exports entering the American market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has committed to increase expenditure on pharmaceuticals through the public health system. This pledge secures that tariffs on these key products will stay at zero for a duration of three years.
This deal comes after earlier statements to dramatically increase duties on patented drug products, with increases floated up to double the cost.
"This deal with the UK reinforces the worldwide climate for innovative medicines and brings long-overdue fairness to American-British pharmaceutical trade," a statement said.
Commercial Impact
Drugs constitute one of the the United Kingdom's biggest goods shipped to the United States, which is by far the largest buyer for major companies like GSK and AstraZeneca.
Statistics indicate that in the one-year period leading up to September, the UK exported medicines valued at billions to the US. This amount made up 17.4% of total UK exports in that span.
"This guarantee safeguards employment, boosts investment and paves the way for the UK to become a global hub for life sciences," a minister remarked.
Key British Pledges
The agreement entails several key commitments from the British government:
- Revised Affordability Limit: The UK will increase the price threshold at which it judges new treatments to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a aim to raise overall NHS spending on drugs from 0.3% of GDP to 0.6% over the coming ten years.
- Rebate Cap: The amount drug companies must return to the NHS to stay within budget will be restricted at 15%. Previously, refunds were more than 20%.
Broader Context
The pact follows a long-running row between the drug companies and the UK government over spending levels and NHS adoption.
This friction were intensified by claims that American customers were paying significantly more for the identical medicines than patients in the Britain and the EU.
Over the last 18 months, several major pharmaceutical investments in the UK have been paused or abandoned, while major funding commitments have been announced toward projects in the United States.
The Science Minister stated that the NHS must invest a greater share on treatments, noting that its spending on drugs had shrunk as a share of its total funding over the past decade.
